Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In a single-center phase 1-2a study, the anti-CD19 chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel produced high rates of complete remission and was associated with serious but mainly reversible toxic effects in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). METHODS: We conducted a phase 2, single-cohort, 25-center, global study of tisagenlecleucel in pediatric and young adult patients with CD19+ relapsed or refractory B-cell ALL. The primary end point was the overall remission rate (the rate of complete remission or complete remission with incomplete hematologic recovery) within 3 months. RESULTS: For this planned analysis, 75 patients received an infusion of tisagenlecleucel and could be evaluated for efficacy. The overall remission rate within 3 months was 81%, with all patients who had a response to treatment found to be negative for minimal residual disease, as assessed by means of flow cytometry. The rates of event-free survival and overall survival were 73% (95% confidence interval [CI], 60 to 82) and 90% (95% CI, 81 to 95), respectively, at 6 months and 50% (95% CI, 35 to 64) and 76% (95% CI, 63 to 86) at 12 months. The median duration of remission was not reached. Persistence of tisagenlecleucel in the blood was observed for as long as 20 months. Grade 3 or 4 adverse events that were suspected to be related to tisagenlecleucel occurred in 73% of patients. The cytokine release syndrome occurred in 77% of patients, 48% of whom received tocilizumab. Neurologic events occurred in 40% of patients and were managed with supportive care, and no cerebral edema was reported. CONCLUSIONS: In this global study of CAR T-cell therapy, a single infusion of tisagenlecleucel provided durable remission with long-term persistence in pediatric and young adult patients with relapsed or refractory B-cell ALL, with transient high-grade toxic effects. (Funded by Novartis Pharmaceuticals; ClinicalTrials.gov number, NCT02435849 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Some immunotherapies have shown promise in this setting, such as dinutuximab administered in combination with cytotoxic therapy in relapsed/refractory neuroblastoma3,4.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“It has been reported that CAR-T cell therapy shows high response rates to B-ALL patients in different age groups [117–119].”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“Any grade 3 or 4 adverse event 19 (25) 33 (44) 8 (11) 4 (6)”
Self-citationLee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Porter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Self-citationMilone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197 · cited 2×
“Increase in aspartate aminotransferase 5 (7) 2 (3) — —”
BackgroundSelf-citationGardner, R. A., Finney, O., Annesley, C., Brakke, H., Summers, C., Leger, K., Bleakley, M., Brown, C., Mgebroff, S., Kelly-Spratt, K. S., et al. (2017) · Blood · doi:10.1182/blood-2017-02-769208 · Cited by 1,121
von Stackelberg, A., Locatelli, F., Zugmaier, G., Handgretinger, R., Trippett, T. M., Rizzari, C., Bader, P., O’Brien, M. M., Brethon, B., Bhojwani, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3301 · Cited by 614 · cited 1×
“Decrease in neutrophil count 1 (1) 6 (8) 1 (1) 1 (1)”
Self-citationSabatino, M., Hu, J., Sommariva, M., Gautam, S., Fellowes, V., Hocker, J. D., Dougherty, S., Qin, H., Klebanoff, C. A., Fry, T. J., et al. (2016) · Blood · doi:10.1182/blood-2015-11-683847 · Cited by 383
Cited by
Items 201–300 of 1,024
CARs versus BiTEs: A Comparison between T Cell–Redirection Strategies for Cancer Treatment
Slaney, C. Y., Wang, P., Darcy, P. K., & Kershaw, M. H. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0297 · Cited by 228
“A clinical trial using continuous infusion of blinatumomab 60 μg/m2/day in NHL (4-fold higher than ALL) has proven to be feasible.”
BackgroundInfluentialDeveloping neoantigen-targeted T cell–based treatments for solid tumors
Yamamoto, T. N., Kishton, R. J., & Restifo, N. P. (2019) · Nature Medicine · doi:10.1038/s41591-019-0596-y · Cited by 238
CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions
Mardiana, S., & Gill, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00697 · Cited by 236
“The optimal duration of CAR T cell persistence for disease response, at least for CD19 CAR T cells, is predicted to be at least 3–6 months (4, 39).”
BackgroundHaen, S. P., Löffler, M. W., Rammensee, H.-G., & Brossart, P. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0387-x · Cited by 222
Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms
Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L., & Kitsis, R. N. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145186 · Cited by 237
CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas
Gang, M., Marin, N. D., Wong, P., Neal, C. C., Marsala, L., Foster, M., Schappe, T., Meng, W., Tran, J., Schaettler, M., et al. (2020) · Blood · doi:10.1182/blood.2020006619 · Cited by 225
Schultz, L. M., Baggott, C., Prabhu, S., Pacenta, H. L., Phillips, C. L., Rossoff, J., Stefanski, H. E., Talano, J.-A., Moskop, A., Margossian, S. P., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.20.03585 · Cited by 220
Self-citationTargeting immune cells for cancer therapy
Gun, S. Y., Lee, S. W. L., Sieow, J. L., & Wong, S. C. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101174 · Cited by 229
The journey of CAR-T therapy in hematological malignancies
Lu, J., & Jiang, G. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01663-0 · Cited by 217
“Kymriah (Tisagenlecleucel) Kymriah was the first approved CAR-T cell product (CD19/FMC63) by FDA on August 31, 2017 indicated, for the treatment of patients (below 25 years of age) with B-cell precursor acute lymphoblastic leukemia (B-ALL) that was in refractory or in second or later relapse [18].”
BackgroundKureshi, C. T., & Dougan, S. K. (2025) · Cancer Cell · doi:10.1016/j.ccell.2024.11.011 · Cited by 213
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia
Mueller, K. T., Waldron, E., Grupp, S. A., Levine, J. E., Laetsch, T. W., Pulsipher, M. A., Boyer, M. W., August, K. J., Hamilton, J., Awasthi, R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0758 · Cited by 228
“S15) closely resembles the duration of remission analyses previously reported (13).”
BackgroundSelf-citation4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling
Philipson, B. I., O’Connor, R. S., May, M. J., June, C. H., Albelda, S. M., & Milone, M. C. (2020) · Science Signaling · doi:10.1126/scisignal.aay8248 · Cited by 232
Self-citationEnhanced safety and efficacy of protease-regulated CAR-T cell receptors
Labanieh, L., Majzner, R. G., Klysz, D., Sotillo, E., Fisher, C. J., Vilches-Moure, J. G., Pacheco, K. Z. B., Malipatlolla, M., Xu, P., Hui, J. H., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.041 · Cited by 216
“…activity in relapsed and refractory B cell malignancies (Ali et al., 2016; Brudno et al., 2018; Fry et al., 2018; Jacoby et al., 2019; Lee et al., 2015; Majzner andMackall, 2019; Maude et al., 2018; Neelapu et al., 2017a; Raje et al., 2019; Schuster et al., 2017, 2019; Wang et al., 2020).”
BackgroundVaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity
Ma, L., Hostetler, A., Morgan, D. M., Maiorino, L., Sulkaj, I., Whittaker, C. A., Neeser, A., Pires, I. S., Yousefpour, P., Gregory, J., et al. (2023) · Cell · doi:10.1016/j.cell.2023.06.002 · Cited by 220
Memory T cell, exhaustion, and tumor immunity
Ando, M., Ito, M., Srirat, T., Kondo, T., & Yoshimura, A. (2020) · Immunological Medicine · doi:10.1080/25785826.2019.1698261 · Cited by 229
Brown, P., Inaba, H., Annesley, C., Beck, J., Colace, S., Dallas, M., DeSantes, K., Kelly, K., Kitko, C., Lacayo, N., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0001 · Cited by 217
Self-citationOtani, I. M., Lehman, H. K., Jongco, A. M., Tsao, L. R., Azar, A. E., Tarrant, T. K., Engel, E., Walter, J. E., Truong, T. Q., Khan, D. A., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.01.025 · Cited by 208
“Interestingly, some patients in CD19 CAR-T-cell therapy trials received IgG-RT (not specified if IVIG or SCIG), and it is not clear to what degree this may have prevented infectious complications.(38,226,228,231,232) In 1 study in which all 30 patients received IgG-RT (not specified if IVIG or SCIG) to maintain IgG le…”
BackgroundCytokines in Pain: Harnessing Endogenous Anti-Inflammatory Signaling for Improved Pain Management
Vanderwall, A. G., & Milligan, E. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03009 · Cited by 218
“To date, there are three FDA approved gene therapies, including Spinraza (nusinersen; anti-sense oligonucleotide for treatment of spinal muscular atrophy type 1) (64, 65), Kymriah (tisagenlecleucel; CAR T-cell therapy for treatment of B-cell precursor acute lymphoblastic leukemia) (66), and Luxturna (voretigene neparv…”
BackgroundMicklethwaite, K. P., Gowrishankar, K., Gloss, B. S., Li, Z., Street, J. A., Moezzi, L., Mach, M. A., Sutrave, G., Clancy, L. E., Bishop, D. C., et al. (2021) · Blood · doi:10.1182/blood.2021010858 · Cited by 226
Dagar, G., Gupta, A., Masoodi, T., Nisar, S., Merhi, M., Hashem, S., Chauhan, R., Dagar, M., Mirza, S., Bagga, P., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04292-3 · Cited by 205
“CAR T-cell therapy has shown a particular clinical benefit in patients suffering from r/r B-precursor ALL with poor prognosis [10, 92, 98, 99].”
BackgroundResultMyers, R. M., Taraseviciute, A., Steinberg, S. M., Lamble, A. J., Sheppard, J., Yates, B., Kovach, A. E., Wood, B., Borowitz, M. J., Stetler-Stevenson, M., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01405 · Cited by 214
“CD19directed chimeric antigen receptor T cells (CD19CAR), in particular, have produced remarkably high complete remission (CR) rates of 70%-97%.(3-11) These successes led to the approval of tisagenlecleucel, a murine-based CD19-CAR, by the US Food and Drug Administration (FDA) in 2017.”
BackgroundMethodSelf-citationDufva, O., Koski, J., Maliniemi, P., Ianevski, A., Klievink, J., Leitner, J., Pölönen, P., Hohtari, H., Saeed, K., Hannunen, T., et al. (2020) · Blood · doi:10.1182/blood.2019002121 · Cited by 224
Campia, U., Moslehi, J. J., Amiri-Kordestani, L., Barac, A., Beckman, J. A., Chism, D. D., Cohen, P., Groarke, J. D., Herrmann, J., Reilly, C. M., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000641 · Cited by 217
Pulsipher, M. A., Han, X., Maude, S. L., Laetsch, T. W., Qayed, M., Rives, S., Boyer, M. W., Hiramatsu, H., Yanik, G. A., Driscoll, T., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0095 · Cited by 204
“Two phase II, single-arm, multicenter global studies [ELIANA, N = 79 (NCT02435849), data cutoff date July 1, 2019; ENSIGN, N = 64 (NCT02228096), data cutoff date May 24, 2019] were conducted including 143 pediatric and young adult patients with CD19+ relapsed or refractory B-cell ALL who were infused with tisagenlecle…”
BackgroundMethodSelf-citationZhang, X., Lu, X.-A., Yang, J., Zhang, G., Li, J., Song, L., Su, Y., Shi, Y., Zhang, M., He, J., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001466 · Cited by 214
“61 (0) 56 (1) 48 (3) 38 (9) 32 (12) 17 (14) 11 (16) 5 (16) 1 (16) CRi Months after CAR-T Ov er all su rv iva l ( % )”
InfluentialCAR-T Cell Therapy: the Efficacy and Toxicity Balance
Chohan, K. L., Siegler, E. L., & Kenderian, S. S. (2023) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-023-00687-7 · Cited by 203
Daei Sorkhabi, A., Mohamed Khosroshahi, L., Sarkesh, A., Mardi, A., Aghebati-Maleki, A., Aghebati-Maleki, L., & Baradaran, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1113882 · Cited by 208
“Remarkable remission with negligible residual disease in a staggering 61 (81%) of 75 treated patients was the groundbreaking result of a recent clinical trial on patients with acute B-cell lymphoblastic leukemia treated with CD19-specific CAR T-cells (111, 112).”
ResultPrinciples of adoptive T cell therapy in cancer
Met, Ö., Jensen, K. M., Chamberlain, C. A., Donia, M., & Svane, I. M. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-018-0703-z · Cited by 213
How I treat relapsed acute lymphoblastic leukemia in the pediatric population
Hunger, S. P., & Raetz, E. A. (2020) · Blood · doi:10.1182/blood.2019004043 · Cited by 211
Chen, G. M., Chen, C., Das, R. K., Gao, P., Chen, C.-H., Bandyopadhyay, S., Ding, Y.-Y., Uzun, Y., Yu, W., Zhu, Q., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1677 · Cited by 207
“Seventy patients had relapsed or refractory B-ALL, and one was a young adult with Hodgkin lymphoma.”
ResultSelf-citationRecent advances in systemic therapy for hepatocellular carcinoma
Zhang, H., Zhang, W., Jiang, L., & Chen, Y. (2022) · Biomarker Research · doi:10.1186/s40364-021-00350-4 · Cited by 214
Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial
Hong, D. S., Van Tine, B. A., Biswas, S., McAlpine, C., Johnson, M. L., Olszanski, A. J., Clarke, J. M., Araujo, D., Blumenschein, G. R., Kebriaei, P., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02128-z · Cited by 203
Whilding, L., Halim, L., Draper, B., Parente-Pereira, A., Zabinski, T., Davies, D., & Maher, J. (2019) · Cancers · doi:10.3390/cancers11050674 · Cited by 209
CAR T cells for brain tumors: Lessons learned and road ahead
Akhavan, D., Alizadeh, D., Wang, D., Weist, M. R., Shepphird, J. K., & Brown, C. E. (2019) · Immunological Reviews · doi:10.1111/imr.12773 · Cited by 214
Heczey, A., Xu, X., Courtney, A. N., Tian, G., Barragan, G. A., Guo, L., Amador, C. M., Ghatwai, N., Rathi, P., Wood, M. S., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02363-y · Cited by 204
“Similar observations have been made with CAR-T cell products—for example, CD19-specific CAR-T cells 45 —and illustrate a distinguishing feature of cell-based therapies versus other classes of drugs.”
MethodFreyer, C. W., & Porter, D. L. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.07.025 · Cited by 216
Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy
Deutsch, E., Chargari, C., Galluzzi, L., & Kroemer, G. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30171-8 · Cited by 210
A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy
Upadhyay, R., Boiarsky, J. A., Pantsulaia, G., Svensson-Arvelund, J., Lin, M. J., Wroblewska, A., Bhalla, S., Scholler, N., Bot, A., Rossi, J. M., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0756 · Cited by 212
Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells
Agarwalla, P., Ogunnaike, E. A., Ahn, S., Froehlich, K. A., Jansson, A., Ligler, F. S., Dotti, G., & Brudno, Y. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01245-x · Cited by 205
Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia
Zhang, S., Li, L., Shen, A., Chen, Y., & Qi, Z. (2020) · Clinical Drug Investigation · doi:10.1007/s40261-020-00917-3 · Cited by 212
Fujiwara, K., Tsunei, A., Kusabuka, H., Ogaki, E., Tachibana, M., & Okada, N. (2020) · Cells · doi:10.3390/cells9051182 · Cited by 199
“CD8α-HD/TMD shares 62.8% AA identity between mice and humans, whereas CD28-HD/TMD shares 66.8% AA identity (Figure 1C).”
BackgroundInfluentialSynthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response
Baeuerle, P. A., Ding, J., Patel, E., Thorausch, N., Horton, H., Gierut, J., Scarfo, I., Choudhary, R., Kiner, O., Krishnamurthy, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10097-0 · Cited by 198
Ottaviano, G., Georgiadis, C., Gkazi, S. A., Syed, F., Zhan, H., Etuk, A., Preece, R., Chu, J., Kubat, A., Adams, S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq3010 · Cited by 199
“Autologous chimeric antigen receptor T cells (CAR T cells) targeting CD19 on refractory and relapsed (R/R) B-ALL are now available as approved therapies (4, 5) and through non-commercial providers (6, 7).”
BackgroundDe novo design of protein logic gates
Chen, Z., Kibler, R. D., Hunt, A., Busch, F., Pearl, J., Jia, M., VanAernum, Z. L., Wicky, B. I. M., Dods, G., Liao, H., et al. (2020) · Science · doi:10.1126/science.aay2790 · Cited by 213
From concept to cure: The evolution of CAR-T cell therapy
Patel, K. K., Tariveranmoshabad, M., Kadu, S., Shobaki, N., & June, C. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.005 · Cited by 180
Self-citationImmune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
Wang, H., Kaur, G., Sankin, A. I., Chen, F., Guan, F., & Zang, X. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0746-1 · Cited by 202
Pillai, V., Muralidharan, K., Meng, W., Bagashev, A., Oldridge, D. A., Rosenthal, J., Van Arnam, J., Melenhorst, J. J., Mohan, D., DiNofia, A. M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000692 · Cited by 206
“Patient characteristics Consecutive patients (n 5 166) with relapsed/refractory B-ALL who received initial CD19-redirected CAR T-cell therapy from 2012 through 2017 were analyzed.(1,5) These included 91 males and 75 females, with a median age of 12 years (range, 1-29).”
BackgroundMethodResultInfluentialSelf-citationCurrent Perspectives in Cancer Immunotherapy
Christofi, T., Baritaki, S., Falzone, L., Libra, M., & Zaravinos, A. (2019) · Cancers · doi:10.3390/cancers11101472 · Cited by 210
“Tisagenlecleucel (anti-CD19) NHL, ALL, DLBCL Humans [46,47]”
Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
Han, X., Wang, Y., Wei, J., & Han, W. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0813-7 · Cited by 200
“However, multicenter clinical trials have demonstrated that the relapse rate of CD19-targeted CAR-T cell therapy is approximately 30% [6], which may be associated with the lack of CAR-T cell persistence and antigen escape, including antigen downregulation or even antigen loss [7].”
BackgroundShah, B. D., Bishop, M. R., Oluwole, O. O., Logan, A. C., Baer, M. R., Donnellan, W. B., O’Dwyer, K. M., Holmes, H., Arellano, M. L., Ghobadi, A., et al. (2021) · Blood · doi:10.1182/blood.2020009098 · Cited by 201
“Encephalopathy 4 (67) 2 (33) 11 (48) 6 (26) 2 (13) 2 (13) 17 (38) 10 (22)”
BackgroundInfluentialPembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy
Chong, E. A., Alanio, C., Svoboda, J., Nasta, S. D., Landsburg, D. J., Lacey, S. F., Ruella, M., Bhattacharyya, S., Wherry, E. J., & Schuster, S. J. (2022) · Blood · doi:10.1182/blood.2021012634 · Cited by 201
Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety
Nguyen, N. T., Huang, K., Zeng, H., Jing, J., Wang, R., Fang, S., Chen, J., Liu, X., Huang, Z., You, M. J., et al. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00982-5 · Cited by 199
“We employed three additional strategies to continue optimizing LiCARs (Supplementary Note 1), including (i) targeting both components to the PM by adding the transmembrane domain of CD8 and/or the homodimeric DAP10 ectodomain 11-13 ; (ii) reordering the positions of intracellular CAR components (Fig.”
InfluentialCurrent updates on generations, approvals, and clinical trials of CAR T-cell therapy
Asmamaw Dejenie, T., Tiruneh G/Medhin, M., Dessie Terefe, G., Tadele Admasu, F., Wale Tesega, W., & Chekol Abebe, E. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2114254 · Cited by 187
“Besides, CAR T-cell therapeutic failure could be the outcome of T-cell exhaustion that leads to limited T-cell proliferation, activity, and persistence.(138,199,210) Additionally, in vivo tonic signaling, T-cell exhaustion, and poor performance can occur as a result of oligomerization of the ScFv of CARs, such as dibo…”
BackgroundSuccesses and challenges in clinical gene therapy
Kohn, D. B., Chen, Y. Y., & Spencer, M. J. (2023) · Gene Therapy · doi:10.1038/s41434-023-00390-5 · Cited by 184
“Since 2017, several additional autologous CAR-T cell therapies targeting CD19 or BCMA have been approved for the treatment of B-cell leukemia, lymphoma, and multiple myeloma (Table 2) [59 – 68].”
BackgroundCAR-T cell performance: How to improve their persistence?
López-Cantillo, G., Urueña, C., Camacho, B. A., & Ramírez-Segura, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.878209 · Cited by 207
Kadauke, S., Myers, R. M., Li, Y., Aplenc, R., Baniewicz, D., Barrett, D. M., Barz Leahy, A., Callahan, C., Dolan, J. G., Fitzgerald, J. C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02477 · Cited by 205
“Time to high, persistent fever, days 3 (2, 9) 2 (1, 4) .”
BackgroundSelf-citationGene editing for immune cell therapies
Bailey, S. R., & Maus, M. V. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0137-8 · Cited by 203
Abbasi, A., Peeke, S., Shah, N., Mustafa, J., Khatun, F., Lombardo, A., Abreu, M., Elkind, R., Fehn, K., de Castro, A., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0838-y · Cited by 203
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
Kirtane, K., Elmariah, H., Chung, C. H., & Abate-Daga, D. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002723 · Cited by 204
Gauthier, J., Bezerra, E. D., Hirayama, A. V., Fiorenza, S., Sheih, A., Chou, C. K., Kimble, E. L., Pender, B. S., Hawkins, R. M., Vakil, A., et al. (2021) · Blood · doi:10.1182/blood.2020006770 · Cited by 205
Genetics and prognosis of ALL in children vs adults
Roberts, K. G. (2018) · Hematology · doi:10.1182/asheducation-2018.1.137 · Cited by 194
Impact of Manufacturing Procedures on CAR T Cell Functionality
Watanabe, N., Mo, F., & McKenna, M. K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.876339 · Cited by 196
Hu, Y., Zhou, Y., Zhang, M., Zhao, H., Wei, G., Ge, W., Cui, Q., Mu, Q., Chen, G., Han, L., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00721-y · Cited by 198
Straathof, K., Flutter, B., Wallace, R., Jain, N., Loka, T., Depani, S., Wright, G., Thomas, S., Cheung, G. W.-K., Gileadi, T., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abd6169 · Cited by 202
“As seen in leukemia CAR-T cell studies (27, 28), we observed prolonged cytopenia in three patients, two of whom had had CRS.”
BackgroundPagliaro, L., Chen, S.-J., Herranz, D., Mecucci, C., Harrison, C. J., Mullighan, C. G., Zhang, M., Chen, Z., Boissel, N., Winter, S. S., et al. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00525-x · Cited by 183
“In the R/R setting, studies have shown CAR-T cell therapies to bring about remission rates of between 70% and 90%, with virtually all responders achieving MRD negativity 26,319,320 .”
Self-citationTapping the RNA world for therapeutics
Lieberman, J. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0054-4 · Cited by 194
Target selection for CAR-T therapy
Wei, J., Han, X., Bo, J., & Han, W. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0758-x · Cited by 195
CAR T-Cell Associated Neurotoxicity: Mechanisms, Clinicopathologic Correlates, and Future Directions
Hunter, B. D., & Jacobson, C. A. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz017 · Cited by 193
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., Claire, G. K., Frank, M. J., Muffly, L., Shiraz, P., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020002732 · Cited by 193
“Age, median (range), y 56 (21-76) 58 (23-76)”
Immunogenic Cell Death and Immunotherapy of Multiple Myeloma
Serrano-del Valle, A., Anel, A., Naval, J., & Marzo, I. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00050 · Cited by 198
“To date CD19 CAR T cells has shown remarkable results on acute lymphoblastic leukemia, chronic lymphocytic leukemia and nonHodgkin lymphoma (Porter et al., 2015; Maude et al., 2018).”
BackgroundSleeping Beauty–engineered CAR T cells achieve antileukemic activity without severe toxicities
Magnani, C. F., Gaipa, G., Lussana, F., Belotti, D., Gritti, G., Napolitano, S., Matera, G., Cabiati, B., Buracchi, C., Borleri, G., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138473 · Cited by 195
Self-citationAntigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells
Singh, N., Frey, N. V., Engels, B., Barrett, D. M., Shestova, O., Ravikumar, P., Cummins, K. D., Lee, Y. G., Pajarillo, R., Chun, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01326-5 · Cited by 196
Self-citationAbramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M., Wang, M., Arnason, J., Purev, E., Maloney, D. G., Andreadis, C., Sehgal, A., et al. (2024) · Blood · doi:10.1182/blood.2023020854 · Cited by 189
Glial injury in neurotoxicity after pediatric CD19‐directed chimeric antigen receptor T cell therapy
Gust, J., Finney, O. C., Li, D., Brakke, H. M., Hicks, R. M., Futrell, R. B., Gamble, D. N., Rawlings‐Rhea, S. D., Khalatbari, H. K., Ishak, G. E., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25502 · Cited by 194
Oh, S., Mao, X., Manfredo-Vieira, S., Lee, J., Patel, D., Choi, E. J., Alvarado, A., Cottman-Thomas, E., Maseda, D., Tsao, P. Y., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01637-z · Cited by 186
“MuSK-CAAR T cell (MuSK-CAART) technology is based on a clinically approved anti-CD19 chimeric antigen receptor T cell (CART-19) therapy that has led to complete and durable remissions of B cell malignancies 15,16 .”
Agarwal, S., Aznar, M. A., Rech, A. J., Good, C. R., Kuramitsu, S., Da, T., Gohil, M., Chen, L., Hong, S.-J. A., Ravikumar, P., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.001 · Cited by 185
Self-citationLickefett, B., Chu, L., Ortiz-Maldonado, V., Warmuth, L., Barba, P., Doglio, M., Henderson, D., Hudecek, M., Kremer, A., Markman, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1303935 · Cited by 178
Xu, Y., Liu, Q., Zhong, M., Wang, Z., Chen, Z., Zhang, Y., Xing, H., Tian, Z., Tang, K., Liao, X., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0732-7 · Cited by 189
Self-citationJain, T., Bar, M., Kansagra, A. J., Chong, E. A., Hashmi, S. K., Neelapu, S. S., Byrne, M., Jacoby, E., Lazaryan, A., Jacobson, C. A., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2019.08.015 · Cited by 191
Stenger, D., Stief, T. A., Kaeuferle, T., Willier, S., Rataj, F., Schober, K., Vick, B., Lotfi, R., Wagner, B., Grünewald, T. G. P., et al. (2020) · Blood · doi:10.1182/blood.2020005185 · Cited by 182
T cell circuits that sense antigen density with an ultrasensitive threshold
Hernandez-Lopez, R. A., Yu, W., Cabral, K. A., Creasey, O. A., Lopez Pazmino, M. D. P., Tonai, Y., De Guzman, A., Mäkelä, A., Saksela, K., Gartner, Z. J., et al. (2021) · Science · doi:10.1126/science.abc1855 · Cited by 189
“Despite the 5 remarkable recent success of using CAR T cells to treat hematologic cancers (5-7), these CAR T cells indiscriminately kill both cancerous and normal B cells, because they both express the target antigen CD19.”
BackgroundPark, J. H., Nath, K., Devlin, S. M., Sauter, C. S., Palomba, M. L., Shah, G., Dahi, P., Lin, R. J., Scordo, M., Perales, M.-A., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02404-6 · Cited by 181
Myers, R. M., Li, Y., Barz Leahy, A., Barrett, D. M., Teachey, D. T., Callahan, C., Fasano, C. C., Rheingold, S. R., DiNofia, A., Wray, L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03458 · Cited by 190
“03), categorized as follows: (1) encephalopathy: encephalopathy, depressed level of consciousness, lethargy, somnolence, memory impairment, confusion, delirium, agitation, irritability, hallucinations, altered mood, or mental status change; (2) speech impairment: aphasia, dysphasia, dysarthria, or word-finding difficu…”
BackgroundSelf-citationWallstabe, L., Göttlich, C., Nelke, L. C., Kühnemundt, J., Schwarz, T., Nerreter, T., Einsele, H., Walles, H., Dandekar, G., Nietzer, S. L., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126345 · Cited by 193
Mechanisms of immune escape in the cancer immune cycle
Tang, S., Ning, Q., Yang, L., Mo, Z., & Tang, S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106700 · Cited by 178
Lamers-Kok, N., Panella, D., Georgoudaki, A.-M., Liu, H., Özkazanc, D., Kučerová, L., Duru, A. D., Spanholtz, J., & Raimo, M. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01382-5 · Cited by 178
“For example, KYMRIAHTM contains the CD3ζ domain to initiate T cell activation and the 4-1BB co-stimulatory domain to enhance expansion and persistency [133], whereas YESCARTATM carries the CD28 co-stimulatory signal instead of 4-1BB [137].”
BackgroundHLA-independent T cell receptors for targeting tumors with low antigen density
Mansilla-Soto, J., Eyquem, J., Haubner, S., Hamieh, M., Feucht, J., Paillon, N., Zucchetti, A. E., Li, Z., Sjöstrand, M., Lindenbergh, P. L., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01621-1 · Cited by 190
Guedan, S., Madar, A., Casado-Medrano, V., Shaw, C., Wing, A., Liu, F., Young, R. M., June, C. H., & Posey, A. D. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133215 · Cited by 189
“Discussion The persistence of CAR-T cells is tightly correlated to the durability of clinical remissions in patients with chronic lymphocytic leukemia (CLL) (7) and ALL (1).”
BackgroundInfluentialSelf-citationVitanza, N. A., Ronsley, R., Choe, M., Seidel, K., Huang, W., Rawlings-Rhea, S. D., Beam, M., Steinmetzer, L., Wilson, A. L., Brown, C., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03451-3 · Cited by 175
CAR T‐cell therapy: Full speed ahead
Sermer, D., & Brentjens, R. (2019) · Hematological Oncology · doi:10.1002/hon.2591 · Cited by 183
“However, treatment‐related toxicities were frequent, with 73% of patients experiencing severe (grade 3 or higher) adverse events (AEs), including 47% developing severe CRS.3 In October 2017, the first CAR T‐cell therapy for lymphoma was approved (axicabtagene ciloleucel) based on results from the phase 2 multicenter Z…”
MethodInfluentialCAR T-Cell Therapy in Hematological Malignancies
Haslauer, T., Greil, R., Zaborsky, N., & Geisberger, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168996 · Cited by 180
“To date, one CAR T-cell therapy is approved by the FDA, namely Kymriah [19] by Novartis, demonstrating marked effects in treating B-ALL, with 81% overall remission within 3 months [20].”
BackgroundCAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies
Knochelmann, H. M., Smith, A. S., Dwyer, C. J., Wyatt, M. M., Mehrotra, S., & Paulos, C. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01740 · Cited by 187
“Furthermore, similar to CD19+ B cell malignancies (9, 35), solid tumors treated with therapeutic CAR T cells can undergo antigen escape due to selection pressure favoring tumor cells lacking the targeted antigen.”
BackgroundPediatric cancer mortality and survival in the United States, 2001‐2016
Siegel, D. A., Richardson, L. C., Henley, S. J., Wilson, R. J., Dowling, N. F., Weir, H. K., Tai, E. W., & Buchanan Lunsford, N. (2020) · Cancer · doi:10.1002/cncr.33080 · Cited by 181
“4386 Cancer October 1, 2020 chimeric antigen receptor T therapy have shown effectiveness for pediatric ALL and may further improve survival for patients with pediatric ALL and reduce chemotherapy-related toxicity.(41,42) Improvements in lymphoma outcomes were seen during the study period, and they may be due to the im…”
BackgroundCAR T cell therapy: inroads to response and resistance
Brown, C. E., & Mackall, C. L. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-018-0119-y · Cited by 187
Cytokine Release Syndrome: Current Perspectives
Murthy, H., Iqbal, M., Chavez, J. C., & Kharfan-Dabaja, M. A. (2019) · ImmunoTargets and Therapy · doi:10.2147/itt.s202015 · Cited by 178
“…cytotoxic immune T cells to target tumor-speci fi c antigens, this immunotherapy platform has resulted in durable remissions in relapsed and/or refractory B-cell non-Hodgkin lymphoma (NHL) and B-cell acute lymphoblastic leukemia (ALL) 1 – 3 and is showing promising early results in multiple myeloma.”
BackgroundNext-Generation CAR T-cell Therapies
Young, R. M., Engel, N. W., Uslu, U., Wellhausen, N., & June, C. H. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1683 · Cited by 179
Self-citationMechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies
Ruella, M., Korell, F., Porazzi, P., & Maus, M. V. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00807-1 · Cited by 175
Wang, D., Prager, B. C., Gimple, R. C., Aguilar, B., Alizadeh, D., Tang, H., Lv, D., Starr, R., Brito, A., Wu, Q., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1243 · Cited by 183
STING agonist promotes CAR T cell trafficking and persistence in breast cancer
Xu, N., Palmer, D. C., Robeson, A. C., Shou, P., Bommiasamy, H., Laurie, S. J., Willis, C., Dotti, G., Vincent, B. G., Restifo, N. P., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20200844 · Cited by 181
“Chimeric antigen receptor (CAR) T cells have substantial activity against CD19-expressing B cell malignancies in humans (Neelapu et al., 2017; Maude et al., 2018).”
BackgroundRuark, J., Mullane, E., Cleary, N., Cordeiro, A., Bezerra, E. D., Wu, V., Voutsinas, J., Shaw, B. E., Flynn, K. E., Lee, S. J., et al. (2020) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2019.09.037 · Cited by 176
“Table 3 Risk Factor Regression Analyses for PROMIS Global Mental Health T Score Variable Coefficient Standard Error P Value Univariate analysis* Demographics Age at time of CAR T therapy 0.30 0.12 .02 Sex (male versus female) 0.01 3.57 1.00 Race (white versus other) 1.59 3.91 .69 Marital status (nonmarried versus marr…”
BackgroundInfluential
Metadata
- Authors
- Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., Qayed, M., De Moerloose, B., Hiramatsu, H., Schlis, K., Davis, K. L., Martin, P. L., Nemecek, E. R., Yanik, G. A., Peters, C., Baruchel, A., Boissel, N., Mechinaud, F., Balduzzi, A., Krueger, J., June, C. H., Levine, B. L., Wood, P., Taran, T., Leung, M., Mueller, K. T., Zhang, Y., Sen, K., Lebwohl, D., Pulsipher, M. A., & Grupp, S. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Oslo University Hospital (NO)
- Hospital Sant Joan de Déu Barcelona (ES)
- University of Minnesota (US)
- Children's Mercy Hospital (US)
- From the Departments of Pediatrics (S.L.M., S.A.G.) and Pathology and Laboratory Medicine (C.H.J., B.L.L.), Perelman School of Medicine, and Abramson Cancer Center (C.H.J., B.L.L.), University of Pennsylvania, and the Division of Oncology, Center for Childhood Cancer Research and Cancer Immunotherapy Program, Children’s Hospital of Philadelphia (S.L.M., S.A.G.) — all in Philadelphia; the Department of Pediatrics and Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern...
- Royal Children's Hospital (AU)
- University of Southern California (US)
- ORCID
- Maude, Shannon L.
- Laetsch, Theodore W.
- Buechner, Jochen
- Rives, Susana
- Boyer, Michael
- Bittencourt, Henrique
- Bader, Peter
- Verneris, Michael R.
- Stefanski, Heather E.
- Qayed, Muna
- Hiramatsu, Hidefumi
- Davis, Kara L.
- Martin, Paul L.
- Nemecek, Eneida R.
- Yanik, Gregory A.
- Peters, Christina
- Boissel, Nicolas
- Mechinaud, Francoise
- Balduzzi, Adriana
- Krueger, Joerg
- June, Carl H.
- Levine, Bruce L.
- Zhang, Yiyun
- Lebwohl, David
- Pulsipher, Michael A.
- Grupp, Stephan A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-02
- Volume
- 378
- Issue
- 5
- Pages
- 439-448
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5996391
- OpenAlex
- W2787301955
- Cited by
- 5,735
- References
- 24
- Citations by year
- 2026: 573 · 2025: 671 · 2024: 734 · 2023: 730 · 2022: 784 · 2021: 788 · 2020: 706 · 2019: 496 · 2018: 242
- FWCI
- 207.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tisagenlecleucel, CAR T-cell therapy, anti-CD19, B-cell acute lymphoblastic leukemia, relapsed/refractory leukemia, pediatric and young adult patients, complete remission, minimal residual disease, event-free survival, overall survival, cytokine release syndrome, neurological adverse events, CAR T cell persistence, tocilizumab, treatment toxicity
- MeSH terms
- Adolescent, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Female, Humans, Infusions, Intravenous, Male, Receptors, Antigen, T-Cell, Remission Induction, Survival Analysis, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.